ImmunoGen, Inc. Shares Acquired by Blair William Co. IL
About 67% of ImmunoGen's investor base is looking to short. The analysis of current outlook of investing in ImmunoGen suggests that many traders are alarmed regarding ImmunoGen's prospects. ImmunoGen's investing sentiment overview a quick insight into current market opportunities from investing in ImmunoGen. Many technical investors use ImmunoGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ImmunoGen |
Blair William Co. IL increased its holdings in shares of ImmunoGen, Inc. by 68.2 percent in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 579,595 shares of the biotechnology companys stock after purchasing an additional 235,000 shares during the quarter.
Read at thelincolnianonline.com
![]() |
ImmunoGen Fundamental Analysis
We analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
ImmunoGen is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
ImmunoGen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoGen stock to make a market-neutral strategy. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics with similar companies.
Peers
ImmunoGen Related Equities
XFOR | X4 Pharmaceuticals | 8.11 | ||||
TGTX | TG Therapeutics | 5.47 | ||||
MCRB | Seres Therapeutics | 4.11 | ||||
AKRO | Akero Therapeutics | 2.87 | ||||
HOOK | Hookipa Pharma | 2.00 | ||||
MDGL | Madrigal Pharmaceuticals | 1.65 | ||||
AXSM | Axsome Therapeutics | 0.89 | ||||
VKTX | Viking Therapeutics | 0.70 | ||||
INZY | Inozyme Pharma | 0.83 | ||||
TERN | Terns Pharmaceuticals | 1.86 | ||||
MREO | Mereo BioPharma | 2.04 | ||||
PDSB | PDS Biotechnology | 2.21 | ||||
ELEV | Elevation Oncology | 5.45 | ||||
HEPA | Hepion Pharmaceuticals | 7.14 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |